Frances Namuswe
FDA investigator
Appears on 2 documents from 2017 to 2018, mostly at sites in California. Most often cites testing and approval or rejection of components, drug product containers, and closures (21 CFR 211.84).
- 2
- Documents on file
- 4.0
- Observations per 483
- 2017
- First seen
- 2018
- Most recent
What they cite most
From 8 observations- 21 CFR 211.84Testing and approval or rejection of components, drug product containers, and closures2
- 21 CFR 211.100Written procedures; deviations1
- 21 CFR 211.111Time limitations on production1
- 21 CFR 211.113Control of microbiological contamination1
- 21 CFR 211.192Production record review1
Activity by year
2017: 1, 2018: 1
Where
California 1 · Switzerland 1
Often inspects with
Is Frances Namuswe coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2018-03-16 | 483 Amgen, IncMar 16, 2018 · Thousand Oaks, California | Thousand Oaks, California | 7 | |
| 2017-12-15 | 483 Lonza AGDec 15, 2017 · Visp, Switzerland | Visp, Switzerland | 1 |
About this profile
What does Frances Namuswe inspect?
Frances Namuswe appears on 2 documents on file covering 2 sites, mostly in California.
What do they cite most often?
21 CFR 211.84 (testing and approval or rejection of components, drug product containers, and closures), followed by 21 CFR 211.100 and 21 CFR 211.111.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Frances Namuswe is dated Mar 16, 2018.